Bayer HealthCare and Onyx Pharmaceuticals (Onyx) have initiated patient enrollment in an international phase III trial. The study is to evaluate Nexavar (sorafenib) tablets for the treatment of
Boehringer Ingelheim has reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the
Abbott has opened a new Nutrition facility at the Research Park on the University of Illinois campus. The company will use the facility to research and develop nutritional
Medgenics has signed a preclinical development and option agreement with an international biopharmaceutical company. The agreement is worth up to $7m in payments that will include funding for
Merck and Schering-Plough have received clearance from the European Commission (EC) under the EC Merger Regulation for their proposed merger. Reportedly, the integration planning teams from Merck and
Cohera Medical (Cohera) has received approval to initiate human clinical trials of its lead product, TissuGlu, in Germany. Receipt of the approval allows Cohera Medical to proceed with
Potentia Pharmaceuticals (Potentia) has entered into licensing and purchase option agreements with Alcon. The agreements provide Alcon with a license to develop Potentia’s leading drug candidate, POT-4, for
Lonza has announced that it has signed an investment agreement, including a right of first refusal for the commercial production of products, with Cilian. The collaboration with Cilian
MPI Research has announced that it will be collaborating with Kineta. MPI Research will assist Kineta with advancing their autoimmune drug development program. The company said that the
Aldevron has announced that the company is expanding into Madison, WI. The new division will produce and sell contract research and manufacturing services marketed under the Aldevron brand.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.